PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry
This study is currently recruiting participants.
Verified November 2011 by BioMarin Pharmaceutical
Sponsor:
BioMarin Pharmaceutical
Information provided by:
BioMarin Pharmaceutical
ClinicalTrials.gov Identifier:
NCT00778206
First received: October 21, 2008
Last updated: November 30, 2011
Last verified: November 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The objective of this study is to evaluate the safety of long-term treatment with Kuvan.
| Condition | Intervention |
|---|---|
|
Phenylketonuria Hyperphenylalaninaemia |
Drug: Sapropterin Dihydrochloride |
| Study Type: | Observational |
| Study Design: | Observational Model: Cohort Time Perspective: Prospective |
| Official Title: | PKUDOS: Phenylketonuria (PKU) Demographic, Outcomes, and Safety Registry |
Resource links provided by NLM:
Genetics Home Reference related topics:
argininosuccinic aciduria
citrullinemia
N-acetylglutamate synthase deficiency
ornithine translocase deficiency
phenylketonuria
succinic semialdehyde dehydrogenase deficiency
tetrahydrobiopterin deficiency
MedlinePlus related topics:
Phenylketonuria
U.S. FDA Resources
Further study details as provided by BioMarin Pharmaceutical:
| Estimated Enrollment: | 3500 |
| Study Start Date: | September 2008 |
| Estimated Primary Completion Date: | September 2023 (Final data collection date for primary outcome measure) |
| Groups/Cohorts | Assigned Interventions |
|---|---|
|
1. PKUDOS Registry
Patients with a confirmed diagnosis of Phenylketonuria (PKU) with hyperphenylalaninemia who have either received Kuvan therapy, or currently receive Kuvan therapy, or intend to begin receiving Kuvan therapy within 90 days of entering the registry.
|
|
|
2. PKU MOMS Subregistry
Patients with PKU who are pregnant at enrollment in the registry or who become pregnant while participating in the registry.
|
Drug: Sapropterin Dihydrochloride
|
Detailed Description:
The PKUDOS program is a voluntary, multicenter, strictly observational program for patients with PKU who have either received Kuvan therapy, or currently receive Kuvan, or intends to begin receiving Kuvan therapy within 90 days of entering the registry.
Eligibility| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Study Population
Diagnosis of Phenylketonuria with hyperphenylalaninemia
Criteria
PKUDOS Registry
Inclusion Criteria:
- Patient has confirmed diagnosis of PKU with hyperphenylalaninemia documented by a Phenylalanine level of greater than or equal to 360 umol/L (6 mg/dL)
- Patient has previously received Kuvan
- Patient is currently receiving Kuvan
- Patient intends to receive Kuvan therapy within 90 days of enrollment into the registry
- The Patient is being followed at a PKUDOS participating center
- Willing and able to provide written authorization or, if under the age of 18 years, provide written assent (if required) and written patient authorization by a parent or legal guardian
- Willing to provide personal health information
Exclusion Criteria:
- Patients are not eligible to participate in PKUDOS if they are participating in a BioMarin-sponsored clinical study of Kuvan
- Patients not previously treated with Kuvan and patients that are unwilling to begin Kuvan therapy within 90 days of entry into the registry
PKU MOMS Subregistry
Inclusion Criteria:
- Willing to enroll in (or are already enrolled in) PKUDOS
- Agree to follow the standard of care for pregnant women with PKU in the United States (NIH, 200, NIH Consensus Statement)
- Agree to be followed by a hospital or PKU clinic offering the standard of care for maternal PKU
- Are within 10 weeks of their last menstrual period
Exclusion Criteria:
- Patients who have not adhered to the standard of care for pregnant women with PKU in the United States are not eligible to participate in PKU MOMS
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00778206
Show 51 Study Locations
Contacts
| Contact: Amy Fowles | 484-374-3254 | afowles@bmrn.com |
Show 51 Study LocationsSponsors and Collaborators
BioMarin Pharmaceutical
Investigators
| Study Director: | Amy Fowles | BioMarin Pharmaceutical |
More Information
No publications provided
| Responsible Party: | BioMarin Pharmaceutical Inc. |
| ClinicalTrials.gov Identifier: | NCT00778206 History of Changes |
| Other Study ID Numbers: | PKUDOS-01, PKUDOS Registry |
| Study First Received: | October 21, 2008 |
| Last Updated: | November 30, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by BioMarin Pharmaceutical:
|
Phenylketonuria Hyperphenylalaninemia PKU Phenylalanine |
Additional relevant MeSH terms:
|
Phenylketonurias Brain Diseases, Metabolic, Inborn Brain Diseases, Metabolic Brain Diseases Central Nervous System Diseases |
Nervous System Diseases Amino Acid Metabolism, Inborn Errors Metabolism, Inborn Errors Genetic Diseases, Inborn Metabolic Diseases |
ClinicalTrials.gov processed this record on May 16, 2013